Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most oversold biotech stocks to invest in. Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported third-quarter adjusted earnings of $0.47 per share on November 4, significantly exceeding analyst projections of$0.05 per share. Revenue also came in significantly higher than the consensus expectations at $66 million. Despite the strong results, the company’s stocks tumbled that day. Investor concerns regarding discontinuation rates for VYKAT XR, the compan ...